Merck, Inc.
🇺🇸United States
A Study to Evaluate Aprepitant for the Prevention of Post-Operative Nausea and Vomiting in Children (MK-0869-219)
Phase 2
Completed
- Conditions
- Post-operative NauseaPost-operative Vomiting
- Interventions
- First Posted Date
- 2012-11-22
- Last Posted Date
- 2018-09-25
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 229
- Registration Number
- NCT01732458
A Study of Intravenous MK-8226 in Participants With Moderate-to-Severe Atopic Dermatitis (MK-8226-003)
- First Posted Date
- 2012-11-22
- Last Posted Date
- 2019-03-15
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 65
- Registration Number
- NCT01732510
A Study Comparing the Use of Deep or Standard Neuromuscular Blockade in Combination With Low or Standard Insufflation Pressures in Participants Undergoing Laparoscopic Cholecystectomy (P07982)
Phase 4
Completed
- Conditions
- Gallbladder Disease
- Interventions
- First Posted Date
- 2012-11-20
- Last Posted Date
- 2018-10-17
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 127
- Registration Number
- NCT01728584
- Locations
- 🇩🇪
Merck Sharp & Dohme GmbH, Haar, Germany
🇮🇹MSD Italia S.r.l., Rome, Italy
A Study to Compare Efficacy and Safety of Tenofovir Used Alone or in Combination With Pegylated Interferon Alpha-2b in Participants With Chronic Hepatitis B and Elevated Alanine Aminotransferase (MK-4031-384)
Phase 4
Withdrawn
- Conditions
- Hepatitis B
- Interventions
- Biological: Pegylated interferon alpha-2b
- First Posted Date
- 2012-11-15
- Last Posted Date
- 2013-09-19
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Registration Number
- NCT01727271
3-Year Observational Virology Follow-up Study in Subjects Who Participated in Studies of Idenix Anti-HCV, Direct Acting Antivirals
Terminated
- Conditions
- Hepatitis C
- First Posted Date
- 2012-11-04
- Last Posted Date
- 2015-04-16
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 145
- Registration Number
- NCT01721265
A Study of the Safety and Efficacy of Anacetrapib (MK-0859) When Added to Ongoing Statin Therapy (MK-0859-021)
Phase 3
Completed
- Conditions
- Hypercholesterolemia
- Interventions
- Drug: Placebo for anacetrapib 100 mgDrug: Placebo for anacetrapib 25 mg
- First Posted Date
- 2012-10-30
- Last Posted Date
- 2017-04-17
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 459
- Registration Number
- NCT01717300
A Study of the Combination Regimen Grazoprevir (MK-5172) and Elbasvir (MK-8742) ± Ribavirin in Participants With Chronic Hepatitis C (MK-5172-035)
Phase 2
Completed
- Conditions
- Hepatitis C
- Interventions
- First Posted Date
- 2012-10-30
- Last Posted Date
- 2021-02-05
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 573
- Registration Number
- NCT01717326
A Study to Assess the Safety and Efficacy of Omarigliptin (MK-3102) in Participants With Type 2 Diabetes Mellitus (T2DM) and Inadequate Glycemic Control (MK-3102-011)
Phase 3
Completed
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- First Posted Date
- 2012-10-30
- Last Posted Date
- 2018-09-10
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 329
- Registration Number
- NCT01717313
A Study of the Safety, Tolerability, and Antiretroviral Activity of Raltegravir (MK-0518) in Combination With Other Antiretroviral Therapies in Russian Children and Adolescents Infected With Human Immunodeficiency Virus (HIV-1) (MK-0518-248)
Phase 2
Completed
- Conditions
- HIV Infection
- Interventions
- Drug: Other Anti-Retroviral Therapy
- First Posted Date
- 2012-10-30
- Last Posted Date
- 2018-08-21
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 32
- Registration Number
- NCT01717287
A Study of the Safety, Tolerance, and Pharmacokinetics of Oral Posaconazole in Immunocompromised Children (P03579)
Phase 1
Terminated
- Conditions
- Fungal Infections
- Interventions
- First Posted Date
- 2012-10-29
- Last Posted Date
- 2018-08-27
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 142
- Registration Number
- NCT01716234